How AI/ML and advanced techniques are enhancing clinical development Lessons learned from use in study design, patient and site ID, safety, and risk-based monitoring Live webinar Tuesday, October 1, 2019 at 11am EDT Clinical trials create vast amounts of disparate data sets, historically generated and retained in silos. Today, integrating, gaining access to and leveraging the breadth of available data requires advanced technologies and innovative approaches. Learn how IQVIA is using artificial intelligence (AI) and machine learning (ML) with advanced and predictive analytics to transform clinical development. IQVIA will share examples of AI/ML and analytics in use today, and cite benefits being generated. Use cases and lessons learned include: • Study design • Site ID & patient population identification • Safety automation • Clinical monitoring/risk-based monitoring Register today and hear how companies are realizing the benefits of AI/ML and advanced techniques to work in their trials — today! Key take-aways: • Using AI/ML and advanced techniques in clinical development is more than just hype — it is greatly enhancing clinical trials today! • Learn how pharmaceutical firms are realizing the benefits of AI/ML and advanced techniques in their trials with better study design, faster site and patient identification, enhanced and automated safety approaches and more informed, faster decision-making with risk-based and centralized monitoring. Presenters: Lucas Glass Global Head of Analytics Center of Excellence, IQVIA Gary Shorter Head of Artificial Intelligence, R&D, IQVIA Rajneesh Patil Head of Process Design & Analytics, Centralized Monitoring, Services, IQVIA Moderator: Lisa Henderson Editorial Director, Applied Clinical Trials Contact us at iqvia.com For technical questions about this webinar, please contact Kristen Moore at kmoore@mmhgroup.com You have received this message because you signed up to receive information from IQVIA. You can update your preferences or if you no longer wish to receive e-mail communication from us, please unsubscribe.